Because c-Myc and CCND1 play triple roles as HR genes, Roniciclib targets and components of an ESC-like tumour active signature (Figs. 5a and S6A), we expected their expression to decrease in response to the potential HR-NB drug Roniciclib. Here, CCND1 is linked to neoplasm.